Logistics & Transportation

Articles

The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic planning across the healthcare system.

 Asembia 2025: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

Asembia 2025: Rethinking the Drug Distribution Process

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market. 

Asembia 2025: A General Landscape of the Pharmaceutical Industry

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ. 

FDA Approves Additional Manufacturing Plant for Ferring’s Adstiladrin

Videos

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

Will Moving Drug Production to the United States Help or Hurt Patients?

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes potential availability challenges brought on by supply chain obstacles.

The Future of Specialty Medicine

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

IATA CEIV Celebrates a Decade of Enhancing Air Cargo Efficiency 

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

Analyzing Tariffs’ Effect on the Biopharmaceutical Supply Chain

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Impact of Pharma Tariffs on Drug Shortages

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies. 